.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
The decision was driven by results from the Phase III CAPItello-281 trial,
The film tells the story of a 70-year-old woman from Kota, Rajasthan, whose persistent cough led to a diagnosis of advanced lung cancer
Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology
The addition of the Halcyon system represents a significant milestone in the hospital’s oncology services
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Clearance marks major shift beyond chemotherapy
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
